Furthermore, activation of the HIF-1α pathway using hypoxia-mimicking agents such as deferoxamine and dimethyloxalylglycine is a promising treatment for bone diseases such as osteoporosis and skeletal fractures (Zhao et al., 2012; Peng et al., 2014; Jia et al., 2016; Kang et al., 2016). This evidence concerns the gene HIF1A and osteoporosis.